Contributions
Abstract: EP1509
Type: ePoster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Background: Health-related quality of life (HRQOL) is an important component of a person´s well being.
Aim: To evaluate overall clinical response and HRQOL in patients treated solely with IFNß-1a sc over the long term. To estimate to which extent HRQOL is related to overall expanded disability status score (EDSS).
Methods: From our clinical database, we queried 111 multiple sclerosis (MS) patients treated exclusively with IFNß-1a sc. RAND-36 domains were compared to age-matched Canadian norms. In addition, group-based trajectory modeling (GBTM) was used to stratify patients to high and low responders based on disability trajectories. High responders are defined as having EDSS~1 with ≤ 1 EDSS change whereas low responders are defined as having EDSS ≥ 3.0 and ≥ 1 EDSS changes over time. Each of the 8 RAND-36 domains is described for the MS patients in both trajectories.
Results: The 111 patients queried consisted of 89 women and 22 men; mean age of onset: 31 years; mean disease duration: 15 years ± 8.9; median EDSS: 1.5 (0-8); treatment duration: 7.6 ± 3.8 years, 84% were remitting-relapsing MS or clinically isolated syndrome. Per GBTM, a predicted 65% patients were high responders and 35% were low responders. Physical function and role limitations due to physical health were less impaired for patients in the low disability trajectories. In 7 of 8 RAND-36 domains, all patients had lower scores than age-matched norms, more so in the low responders. Pain was similar in all groups. The low responders had a higher age and longer disease duration at treatment initiation.
Conclusion: A stable low disability trajectory was observed in 65% of patients only ever treated with IFNß-1a sc. However, HRQOL was impaired in all patients.
Disclosure: This study has been funded by an unrestricted grant from EMDSerono.
Pierre Duquette has received honoraria for animating and attending advisory boards and CME events, financial support to attend meetings, and for investigator-initiated trials from: EMDSerono, Biogen-Idec, Genzyme, Novartis, and TEVA Neuroscience. Stanley Hum, Catherine Bigras, Elaine Roger and Isabelle Rouleau report no disclosures.
Abstract: EP1509
Type: ePoster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Background: Health-related quality of life (HRQOL) is an important component of a person´s well being.
Aim: To evaluate overall clinical response and HRQOL in patients treated solely with IFNß-1a sc over the long term. To estimate to which extent HRQOL is related to overall expanded disability status score (EDSS).
Methods: From our clinical database, we queried 111 multiple sclerosis (MS) patients treated exclusively with IFNß-1a sc. RAND-36 domains were compared to age-matched Canadian norms. In addition, group-based trajectory modeling (GBTM) was used to stratify patients to high and low responders based on disability trajectories. High responders are defined as having EDSS~1 with ≤ 1 EDSS change whereas low responders are defined as having EDSS ≥ 3.0 and ≥ 1 EDSS changes over time. Each of the 8 RAND-36 domains is described for the MS patients in both trajectories.
Results: The 111 patients queried consisted of 89 women and 22 men; mean age of onset: 31 years; mean disease duration: 15 years ± 8.9; median EDSS: 1.5 (0-8); treatment duration: 7.6 ± 3.8 years, 84% were remitting-relapsing MS or clinically isolated syndrome. Per GBTM, a predicted 65% patients were high responders and 35% were low responders. Physical function and role limitations due to physical health were less impaired for patients in the low disability trajectories. In 7 of 8 RAND-36 domains, all patients had lower scores than age-matched norms, more so in the low responders. Pain was similar in all groups. The low responders had a higher age and longer disease duration at treatment initiation.
Conclusion: A stable low disability trajectory was observed in 65% of patients only ever treated with IFNß-1a sc. However, HRQOL was impaired in all patients.
Disclosure: This study has been funded by an unrestricted grant from EMDSerono.
Pierre Duquette has received honoraria for animating and attending advisory boards and CME events, financial support to attend meetings, and for investigator-initiated trials from: EMDSerono, Biogen-Idec, Genzyme, Novartis, and TEVA Neuroscience. Stanley Hum, Catherine Bigras, Elaine Roger and Isabelle Rouleau report no disclosures.